Carlson Fish Oils - Part of a Major Research Study
A study is in progress investigating the effect of intervention factors on patients with type 2 diabetes mellitus and coronary artery disease (CAD).
CAD is the major complication of both type 1 and type 2 diabetes mellitus. Diabetes is increasing at an epidemic rate with 151 million cases in 2000 forecasted to double by 2025. Guidelines are needed to address this problem. The new study is aimed at evaluating various intervention factors.
Factors being investigated as part of a possible treatment program are:
The use of weight management
Lowering cholesterol, blood pressure, and triglycerides
Diet and exercise
A total of 2,368 patients have been enrolled at 49 clinical centers in North America, South America, and Europe. The study started in 2005 and is expected to extend to at least May 2007.
Carlson Laboratories is supplying the fish oil needed in the study. Other firms such as Abbott Laboratories, Bayer Diagnostics, Eli Lilly, Merck & Co., and Pfizer Inc. are supplying drugs and equipment for this study.